Loading
A phase 2 trial of DNX-2401 run by University of California, San Francisco, now recruiting.
Combination Therapy for the Treatment of Diffuse Midline Gliomas is a phase 2 interventional study registered as NCT05009992 by University of California, San Francisco, with 360 participants planned, started 2021-10-20. Conditions recorded: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma and WHO Grade III Glioma. Interventions recorded: ONC201, Radiation Therapy, Paxalisib and DNX-2401.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/